Q3 2023 · 13F-HR
venBio Partners LLCholdings as filed
Filed 2023-11-14 · accession 0000905148-23-001445
$352.7M
Reported value
8
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 75525N107 | — | RAYZEBIO INC | $114.5M | 32.5% | 5,158,162 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $89.0M | 25.2% | 4,264,672 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $46.6M | 13.2% | 9,699,925 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $39.2M | 11.1% | 3,852,470 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $33.9M | 9.62% | 1,035,396 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $26.4M | 7.47% | 758,800 | Common | SOLE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $1.9M | 0.55% | 2,914,255 | Common | SOLE |
| 45258K109 | — | IMPEL PHARMACEUTICALS INC | $1.2M | 0.34% | 2,759,791 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.